Sepsis - Pipeline Review, H2 2018

Sepsis - Pipeline Review, H2 2018


  • Products Id :- GMDHC10619IDB
  • |
  • Pages: 278
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Sepsis-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sepsis-Pipeline Review, H2 2018, provides an overview of the Sepsis (Infectious Disease) pipeline landscape.

Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function and abdominal pain. The predisposing factors include age and weakened immune systems. Treatment includes antibiotics and vasopressor

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sepsis-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Sepsis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sepsis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Sepsis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 9, 4, 2, 52, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 23 and 2 molecules, respectively.

Sepsis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sepsis (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Sepsis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Sepsis (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Sepsis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Sepsis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Sepsis (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Sepsis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 5

Sepsis-Overview 6

Sepsis-Therapeutics Development 7

Sepsis-Therapeutics Assessment 22

Sepsis-Companies Involved in Therapeutics Development 32

Sepsis-Drug Profiles 50

Sepsis-Dormant Projects 249

Sepsis-Discontinued Products 255

Sepsis-Product Development Milestones 256

Appendix 266

List of Figures

Number of Products under Development for Sepsis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

List of Tables

Number of Products under Development for Sepsis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Universities/Institutes, H2 2018

Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Sepsis-Pipeline by Adrenomed AG, H2 2018

Sepsis-Pipeline by Am-Pharma BV, H2 2018

Sepsis-Pipeline by Arch Biopartners Inc, H2 2018

Sepsis-Pipeline by Asahi Kasei Corp, H2 2018

Sepsis-Pipeline by Atox Bio Ltd, H2 2018

Sepsis-Pipeline by Aurigene Discovery Technologies Ltd, H2 2018

Sepsis-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Sepsis-Pipeline by Bristol-Myers Squibb Co, H2 2018

Sepsis-Pipeline by Cell2B Advanced Therapeutics SA, H2 2018

Sepsis-Pipeline by Cells for Cells SA, H2 2018

Sepsis-Pipeline by Chiome Bioscience Inc, H2 2018

Sepsis-Pipeline by Cilian AG, H2 2018

Sepsis-Pipeline by Cynata Therapeutics Ltd, H2 2018

Sepsis-Pipeline by CytaCoat AB, H2 2018

Sepsis-Pipeline by Dr. Franz Kohler Chemie GmbH, H2 2018

Sepsis-Pipeline by Endacea Inc, H2 2018

Sepsis-Pipeline by Enlivex Therapeutics Ltd, H2 2018

Sepsis-Pipeline by Evec Inc, H2 2018

Sepsis-Pipeline by Expression Drug Designs LLC, H2 2018

Sepsis-Pipeline by Immunwork Inc, H2 2018

Sepsis-Pipeline by InflaRx NV, H2 2018

Sepsis-Pipeline by Integrated BioTherapeutics Inc, H2 2018

Sepsis-Pipeline by Lead Discovery Center GmbH, H2 2018

Sepsis-Pipeline by Mochida Pharmaceutical Co Ltd, H2 2018

Sepsis-Pipeline by Nosopharm SAS, H2 2018

Sepsis-Pipeline by OncoImmune Inc, H2 2018

Sepsis-Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Sepsis-Pipeline by Opsona Therapeutics Ltd, H2 2018

Sepsis-Pipeline by ProThera Biologics Inc, H2 2018

Sepsis-Pipeline by Ra Pharmaceuticals Inc, H2 2018

Sepsis-Pipeline by Recce Ltd, H2 2018

Sepsis-Pipeline by Ribomic Inc, H2 2018

Sepsis-Pipeline by Rimonyx Pharmaceuticals Ltd, H2 2018

Sepsis-Pipeline by SciClone Pharmaceuticals Inc, H2 2018

Sepsis-Pipeline by SetLance srl, H2 2018

Sepsis-Pipeline by Shionogi & Co Ltd, H2 2018

Sepsis-Pipeline by Sirtex Medical Ltd, H2 2018

Sepsis-Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018

Sepsis-Pipeline by Syntiron LLC, H2 2018

Sepsis-Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Sepsis-Pipeline by Therakind Ltd, H2 2018

Sepsis-Pipeline by Therashock LLC, H2 2018

Sepsis-Pipeline by TiGenix NV, H2 2018

Sepsis-Pipeline by Vascular BioSciences, H2 2018

Sepsis-Dormant Projects, H2 2018

Sepsis-Dormant Projects, H2 2018 (Contd..1), H2 2018

Sepsis-Dormant Projects, H2 2018 (Contd..2), H2 2018

Sepsis-Dormant Projects, H2 2018 (Contd..3), H2 2018

Sepsis-Dormant Projects, H2 2018 (Contd..4), H2 2018

Sepsis-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Adrenomed AG

Am-Pharma BV

Arch Biopartners Inc

Asahi Kasei Corp

Atox Bio Ltd

Aurigene Discovery Technologies Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cell2B Advanced Therapeutics SA

Cells for Cells SA

Chiome Bioscience Inc

Cilian AG

Cynata Therapeutics Ltd

CytaCoat AB

Dr. Franz Kohler Chemie GmbH

Endacea Inc

Enlivex Therapeutics Ltd

Evec Inc

Expression Drug Designs LLC

Immunwork Inc

InflaRx NV

Integrated BioTherapeutics Inc

Lead Discovery Center GmbH

Mochida Pharmaceutical Co Ltd

Nosopharm SAS

OncoImmune Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

ProThera Biologics Inc

Ra Pharmaceuticals Inc

Recce Ltd

Ribomic Inc

Rimonyx Pharmaceuticals Ltd

SciClone Pharmaceuticals Inc

SetLance srl

Shionogi & Co Ltd

Sirtex Medical Ltd

SK Biopharmaceuticals Co Ltd

Syntiron LLC

Takeda Pharmaceutical Co Ltd

Therakind Ltd

Therashock LLC

TiGenix NV

Vascular BioSciences

Sepsis Therapeutic Products under Development, Key Players in Sepsis Therapeutics, Sepsis Pipeline Overview, Sepsis Pipeline, Sepsis Pipeline Assessment

select a license
Single User License
USD 2000 INR 141960
Site License
USD 4000 INR 283920
Corporate User License
USD 6000 INR 425880

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com